StoneX Group’s Citius Pharmaceuticals CTXR Stock Holding History

StoneX Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20K	Buy	+36,414	New	+$21.5K	﹤0.01%	1755
2023 Q1	–	Sell	-444	Closed	-$8.77K	–	731
2022 Q4	$8.77K	Buy	+444	New	+$12.1K	﹤0.01%	559

Other funds holding CTXR

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Asset Advisory Group Kinnelon, New Jersey $232M AUM 16.51% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Princeton Global Asset Management Princeton, New Jersey $692M AUM 20.31% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

StoneX Group's CTXR Position: Q3 2026 in Review

StoneX Group opened a new position in Citius Pharmaceuticals (CTXR) in Q3 2026: 36,414 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #1755 among its holdings. This is a return to the name: StoneX Group previously reported a position in CTXR as recently as Q4 2022.

StoneX Group first reported a position in CTXR in Q4 2022 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.

StoneX Group held 36,414 shares of Citius Pharmaceuticals worth $20K as of Q3 2026.
Citius Pharmaceuticals was a new StoneX Group position in Q3 2026.
Citius Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1755 holding.
StoneX Group first reported a position in Citius Pharmaceuticals in Q4 2022 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.